ContactDictionary

Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  fludeoxyglucose F 18
Find trials that include:  Any drugs shown
Results 1-25 of 60 for your search:
Start Over
18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients with Cancer Receiving Anti-Angiogenesis Therapy
Status: Active
Phase: Phase II, Phase I
Type: Diagnostic
Age: 18 and over
Trial IDs: VARIMG0002, NCI-2013-00535, NCT01806675
Fludeoxyglucose F 18-PET/CT Imaging in Assessing the Tumor and Planning Neck Surgery in Patients with Newly Diagnosed Head and Neck Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Health services research
Age: 18 and over
Trial IDs: ACRIN 6685, NCI-2011-01972, CA80098, CDR0000654703, NCT00983697
Response-Based Therapy Assessed by PET Scan in Treating Patients with Stage IA-IIB Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 to 60
Trial IDs: CALGB-50801, NCI-2011-02034, CDR0000669076, NCT01118026
PET-Directed Therapy in Treating Patients with Limited-Stage Diffuse Large B-Cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1001, NCI-2011-02673, CDR0000700624, SWOG-S1001, NCT01359592
Cabozantinib in Treating Patients with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Involvement
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-208, NCI-2011-03519, XL184-IST12, NCT01441947
Gene and Vaccine Therapy in Treating Patients with Advanced Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 and over
Trial IDs: 12-000153, NCI-2012-01548, NCT01697527
FDG-PET in Predicting Treatment Response in Patients with Newly Diagnosed Stage II-IV Breast Cancer Receiving Pertuzumab and Trastuzumab Prior to Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TBCRC 026, NCI-2014-01543, NA_00080994, NCI-2014-00245, NCT01937117
Total Marrow and Lymphoid Irradiation and Chemotherapy before Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Lymphocytic or Myelogenous Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 60
Trial IDs: 14012, NCI-2014-00639, 105023, 108097, 112566, NCT02094794
Nelfinavir Mesylate and Chemoradiotherapy in Treating Patients With Locally Advanced, Human Papilloma Virus Negative, Squamous Cell Carcinoma of the Larynx
Status: Active
Phase: Phase II
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: UPCC 15313, NCI-2014-00591, NCT02207439
Fludeoxyglucose F-18 PET/MRI in Predicting Treatment Response in Patients with Newly Diagnosed Stage II or III Rectal Cancer Undergoing Chemoradiation Therapy
Status: Active
Phase: Phase II
Type: Diagnostic
Age: 18 and over
Trial IDs: CC#144513, NCI-2015-00980, 133123, 144513, NCT02233595
18F-FSPG PET/CT in Imaging Patients with Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules
Status: Active
Phase: Phase II
Type: Diagnostic
Age: 55 to 74
Trial IDs: VICC THO 1524, NCI-2015-00748, THO 1524, NCT02448225
Genomic Based Assignment of Therapy in Treating Patients with Progressive Metastatic Urothelial Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: P152399, NCI-2016-00966, 16-C-0121, NCT02788201
FLARE RT for Patients with Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 9599, NCI-2016-00543, NCT02773238
C11-AMT PET Imaging in Predicting Tumor Response to Pembrolizumab in Patients with Metastatic Melanoma
Status: Not yet active
Phase: Phase II
Type: Diagnostic
Age: 18 and over
Trial IDs: LCCC1531, NCI-2017-00717, NCT03089606
Pembrolizumab and Involved Site Radiation Therapy in Treating Patients with Early Stage Relapsed or Refractory Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 17-054, NCI-2017-01142, NCT03179917
Stereotactic Radiation Therapy in Treating Patients With Liver Metastases
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 09-051, NCI-2013-00407, NCT01360606
Sirolimus and Vismodegib in Treatment of Patients with Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: MC1111, NCI-2011-03809, NCT01537107
Ipilimumab or Nivolumab in Treating Patients with Relapsed Hematologic Malignancies after Donor Stem Cell Transplant
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9204, NCI-2013-00739, 12-537, NCT01822509
18F-FDG PET/CT before Surgery in Mapping Lymph Nodes in Patients with Stage IB Cervical Cancer or High-Grade Endometrial Cancer
Status: Active
Phase: Phase I
Type: Diagnostic
Age: 18 to 75
Trial IDs: 14-222, NCI-2014-02552, NCT02285192
18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Diagnostic
Age: 18 and over
Trial IDs: 2014-0616, NCI-2015-00525, NCT02390635
Sapanisertib and Alisertib in Treating Patients with Incurable Refractory Solid Tumors or Metastatic Triple-Negative Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: 15-1135, NCI-2016-00443, NCT02719691
Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients with Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 16 and over
Trial IDs: 15-001433, NCI-2016-00201, NCT02775292
18F-FDG PET or 1H-MRSI in Assessing Tumor Activity in Younger Patients with Brain Tumors
Status: Active
Phase: No phase specified
Type: Diagnostic, Natural history/Epidemiology
Age: 1 to 21
Trial IDs: 03-C-0278, NCI-2013-02042, 030278, NCT00070512, NCI-03-C-0278, NCT00067821
18F NaF/18F FDG PET/MRI in Detecting Skeletal Metastases in Patients with Stage III-IV Breast Cancer or Stage II-IV Prostate Cancer
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: BONE0001, NCI-2015-01340, 351, SQL 96754, NCT00375830
Fludeoxyglucose F-18 and Fluorine F18 FDHT Positon Emission Tomography in Treating Patients with Progressive Prostate Cancer
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: Not specified
Trial IDs: 00-095, NCI-2016-01615, NCT00588185
Start Over